They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

TD Cowen made a significant adjustment to its stance on Merck (NSE:PROR) shares, downgrading the pharmaceutical giant from "Buy" to "Hold". Accompanying the downgrade, the firm also revised its price ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc.

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...